Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial-Reference-Cited by-同舟云学术

Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial

Published:2019-01 Issue: Volume:107 Page:100-114
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Suenaga Mitsukuni,Stintzing Sebastian,Cao Shu,Zhang Wu,Yang Dongyun,Ning Yan,Okazaki Satoshi,Berger Martin D.,Miyamoto Yuji,Schirripa Marta,Soni Shivani,Barzi Afsaneh,Heinemann Volker,Lenz Heinz-Josef

Funder

Swiss Cancer League

Werner and Hedy Berger-Janser Foundation

Japan Society for the Promotion of Science

National Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial;Stintzing;Lancet Oncol,2016

2. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial;Venook;JAMA,2017